 |
9 Diseases |  |
1 Trial |
|
1 Trial |  |
139 News |  |
| 12» |
- ||| otilimab (GSK3196165) / GSK
P3 data, Journal: Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2). (Pubmed Central) - Nov 13, 2023
P3
Although otilimab demonstrated superiority to placebo in ACR20, CDAI LDA and HAQ-DI, improved symptoms, and had an acceptable safety profile, it was inferior to tofacitinib.
- ||| otilimab (GSK3196165) / GSK, Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
P3 data, Journal: Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3). (Pubmed Central) - Nov 13, 2023
P3
Although otilimab demonstrated superiority to placebo in ACR20, CDAI LDA and HAQ-DI, improved symptoms, and had an acceptable safety profile, it was inferior to tofacitinib. Otilimab demonstrated an acceptable safety profile but failed to achieve the primary end point of ACR20 and improve secondary end points versus placebo or demonstrate non-inferiority to sarilumab in this patient population.
- ||||||||| otilimab (GSK3196165) / GSK
Trial termination: contRAst X: Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Oct 10, 2023
P3, N=2916, Terminated, Sponsor: GlaxoSmithKline
Completed --> Terminated; Study is early terminated due to Limited efficacy demonstrated in the contRAst program does not support a suitable benefit/risk profile for otilimab as a potential treatment for RA. GSK has decided not to progress with regulatory submissions.
- ||||||| otilimab (GSK3196165) / GSK
Trial completion: contRAst X: Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Apr 5, 2023
P3, N=2916, Completed, Sponsor: GlaxoSmithKline
GSK has decided not to progress with regulatory submissions. Active, not recruiting --> Completed
- ||||||||| otilimab (GSK3196165) / GSK
Trial termination, Combination therapy: contRAst 2: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) (clinicaltrials.gov) - Feb 24, 2023
P3, N=1764, Terminated, Sponsor: GlaxoSmithKline
Active, not recruiting --> Terminated; Only Asia cohort is early terminated.Limited efficacy demonstrated in the contRAst program does not support a suitable benefit/risk profile for otilimab as a potential treatment for RA. GSK has decided not to progress with regulatory submissions.
- | otilimab (GSK3196165) / GSK
Enrollment change, Trial completion date, Trial initiation date, Trial withdrawal, Trial primary completion date: A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab (clinicaltrials.gov) - Jan 26, 2023
P1, N=0, Withdrawn, Sponsor: GlaxoSmithKline
GSK has decided not to progress with regulatory submissions. N=12 --> 0 | Trial completion date: Jun 2022 --> May 2023 | Initiation date: Mar 2022 --> Feb 2023 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2022 --> May 2023
- ||||| otilimab (GSK3196165) / GSK
Enrollment closed: contRAst X: Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Jan 10, 2023
P3, N=2916, Active, not recruiting, Sponsor: GlaxoSmithKline
N=12 --> 0 | Trial completion date: Jun 2022 --> May 2023 | Initiation date: Mar 2022 --> Feb 2023 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2022 --> May 2023 Recruiting --> Active, not recruiting
- |||| otilimab (GSK3196165) / GSK
Trial completion date, Trial primary completion date: contRAst X: Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Dec 5, 2022
P3, N=3000, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Trial completion date: Apr 2024 --> Feb 2023 | Trial primary completion date: Apr 2024 --> Feb 2023
- |||||| otilimab (GSK3196165) / GSK
Clinical: GSK announced they will halt development of Otilimab (anti-GM-CSF mAb) to treat #RA; decisioin based on negative results from phase 3 ContRAst-3 study, that failed to meet ACR20 primary endpoint in RA pts who failed bDMARDs or JAKi https://t.co/cDqcYKOjSa (Twitter) - Nov 1, 2022
- || otilimab (GSK3196165) / GSK
As a result of GSK's PhII otilimab trial failing to meet its one of its three endpoints, the pharma is scrapping plans for regulatory submissions. https://t.co/w2WoNmr3GD (Twitter) - Oct 30, 2022
- || otilimab (GSK3196165) / GSK
.@GSK licensed global rights to #otilimab in 2013, paying @MorphoSys €22.5 million up front. Another €423 million in payments were tied to milestones. Shares of $MOR dipped a bit on the $GSK news. (Twitter) - Oct 28, 2022
- ||| otilimab (GSK3196165) / GSK
Trial completion date, Combination therapy: contRAst 2: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) (clinicaltrials.gov) - Oct 24, 2022
P3, N=1764, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial completion date: Apr 2024 --> Feb 2023 | Trial primary completion date: Apr 2024 --> Feb 2023 Trial completion date: Sep 2022 --> Feb 2023
- ||||||| otilimab (GSK3196165) / GSK
Trial completion, Combination therapy: contRAst 1: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (clinicaltrials.gov) - Oct 24, 2022
P3, N=1537, Completed, Sponsor: GlaxoSmithKline
Trial completion date: Sep 2022 --> Feb 2023 Active, not recruiting --> Completed
- | otilimab (GSK3196165) / GSK
Journal: A Randomised trial of anti-GM-CSF Otilimab in severe COVID-19 pneumonia (OSCAR). (Pubmed Central) - Oct 14, 2022
P2
There was no significant difference in the proportion of patients alive and free of respiratory failure at Day 28. However, despite the lack of clinical benefit, a reduction in inflammatory markers was observed with otilimab, in addition to an acceptable safety profile.
- || otilimab (GSK3196165) / GSK
New P1 trial: A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab (clinicaltrials.gov) - Mar 31, 2022
P1, N=12, Not yet recruiting, Sponsor: GlaxoSmithKline
- ||||||| otilimab (GSK3196165) / GSK
Trial completion, Combination therapy: contRAst 3: Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors (clinicaltrials.gov) - Mar 16, 2022
P3, N=550, Completed, Sponsor: GlaxoSmithKline
However, despite the lack of clinical benefit, a reduction in inflammatory markers was observed with otilimab, in addition to an acceptable safety profile. Active, not recruiting --> Completed
- | otilimab (GSK3196165) / GSK
Journal: Detection and Modulation of Olfactory Sensing Receptors in Carnivorous Rainbow Trout (Oncorhynchus mykiss) Fed from First Feeding with Plant-Based Diet. (Pubmed Central) - Mar 15, 2022
Gene expression after feeding demonstrated the importance in olfactory sensing perception of some OLFC (olfcg6) and MOR (mor103, -107, -112, -113, -133) receptor family genes in RT...Results indicated an impact of a plant-based diet on the regulation of olfactory sensing pathways as well as influence on monoaminergic neurotransmission in brain areas related to olfactory-driven behaviors. The overall findings suggest that feeding behavior is mediated through olfactory sensing detection and olfactory-driven behavior pathways in RT.
- |||| otilimab (GSK3196165) / GSK
Trial completion date, Trial primary completion date: contRAst X: Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Nov 15, 2021
P3, N=3000, Recruiting, Sponsor: GlaxoSmithKline
The overall findings suggest that feeding behavior is mediated through olfactory sensing detection and olfactory-driven behavior pathways in RT. Trial completion date: Sep 2023 --> Apr 2024 | Trial primary completion date: Sep 2023 --> Apr 2024
- ||||| otilimab (GSK3196165) / GSK
Enrollment closed, Combination therapy: contRAst 2: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) (clinicaltrials.gov) - Sep 27, 2021
P3, N=1674, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial completion date: Sep 2023 --> Apr 2024 | Trial primary completion date: Sep 2023 --> Apr 2024 Recruiting --> Active, not recruiting
- |||| otilimab (GSK3196165) / GSK
Trial completion: OSCAR: Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease (clinicaltrials.gov) - Sep 14, 2021
P2, N=1156, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || otilimab (GSK3196165) / GSK
$MOR Otilimab Ph2 data in COVID-19 - H2'21 Conferences #PAINWeek - 7-11 Sept #IMW2021 - 8-11 Sept #HFSA2021 - 10-13 Sept Roadshows $BCART - EU group call - 6-7 Sept at 9am CET $GLPG - virtual RS - 7 Sept $BIOVIC - virtual RS - 7-10 Sept 3/3 (Twitter) - Sep 6, 2021
- ||||| otilimab (GSK3196165) / GSK
Enrollment closed, Trial primary completion date, Combination therapy: contRAst 1: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (clinicaltrials.gov) - Aug 23, 2021
P3, N=1537, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2021 --> Sep 2021
- ||||| otilimab (GSK3196165) / GSK
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy: contRAst 3: Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors (clinicaltrials.gov) - Aug 18, 2021
P3, N=550, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2021 --> Sep 2021 Recruiting --> Active, not recruiting | Trial completion date: Jul 2022 --> Feb 2022 | Trial primary completion date: Mar 2022 --> Sep 2021
- otilimab (GSK3196165) / GSK
[VIRTUAL] Late Breaking Abstract - Enhanced immune activation pathways enriched in patients =70 years with severe COVID-19 () - Jul 29, 2021 - Abstract #ERS2021ERS_4009;
P2
These analyses reinforce the need for personalized treatment of severe COVID-19 and build rationale for poor outcomes in specific patient groups including older age. Funded by GSK; medical writing support provided by Fishawack Indicia Ltd, funded by GSK.
- ||| otilimab (GSK3196165) / GSK
Enrollment closed: OSCAR: Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease (clinicaltrials.gov) - Jul 22, 2021
P2, N=1157, Active, not recruiting, Sponsor: GlaxoSmithKline
Funded by GSK; medical writing support provided by Fishawack Indicia Ltd, funded by GSK. Recruiting --> Active, not recruiting
- |||| otilimab (GSK3196165) / GSK
Trial completion date, Trial primary completion date, Combination therapy: contRAst 1: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (clinicaltrials.gov) - Mar 15, 2021
P3, N=1500, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Trial completion date: May 2022 --> Nov 2022 | Trial primary completion date: May 2022 --> Dec 2021
- |||| otilimab (GSK3196165) / GSK
Trial completion date, Trial primary completion date, Combination therapy: contRAst 2: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) (clinicaltrials.gov) - Mar 15, 2021
P3, N=1500, Recruiting, Sponsor: GlaxoSmithKline
Trial completion date: May 2022 --> Nov 2022 | Trial primary completion date: May 2022 --> Dec 2021 Trial completion date: May 2022 --> Nov 2022 | Trial primary completion date: May 2022 --> Dec 2021
- |||| otilimab (GSK3196165) / GSK
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date: OSCAR: Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease (clinicaltrials.gov) - Mar 8, 2021
P2, N=1150, Recruiting, Sponsor: GlaxoSmithKline
Trial completion date: May 2022 --> Nov 2022 | Trial primary completion date: May 2022 --> Dec 2021 Active, not recruiting --> Recruiting | N=800 --> 1150 | Trial completion date: Jan 2021 --> Aug 2021 | Trial primary completion date: Jan 2021 --> Aug 2021
- |||| otilimab (GSK3196165) / GSK
Clinical: GSKs RCT showed otilimab (investigational anti-GM-CSF Ab) in severe COVID-19, was not superior to SOC for the primary endpoint - the proportion alive and free of respiratory failure at 28 days (but was effective in pts >70 yrs (65% vs 46%) https://t.co/OHvWGGlgKv (Twitter) - Mar 3, 2021
- || otilimab (GSK3196165) / GSK, lenzilumab (KB003) / Humanigen, Emergent Biosolutions
If you like otilimab in #COVID19 then you will LOVE Lenzilumab in #COVID19 GM-CSF $HGEN (Twitter) - Feb 26, 2021
- ||| otilimab (GSK3196165) / GSK
Enrollment closed: OSCAR: Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease (clinicaltrials.gov) - Dec 22, 2020
P2, N=800, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Recruiting | N=800 --> 1150 | Trial completion date: Jan 2021 --> Aug 2021 | Trial primary completion date: Jan 2021 --> Aug 2021 Recruiting --> Active, not recruiting
- |||| otilimab (GSK3196165) / GSK
Clinical: “there were improvements compared with placebo in disease activity scores. Of note, patients reported significant improvement in pain and physical function, supporting further clinical development of otilimab in rheumatoid arthritis.“ (Twitter) - Oct 9, 2020
- |||| otilimab (GSK3196165) / GSK
Clinical: Study of 222 RA pts on MTX given anti-GMCSF (otilimab) 22·5 mg, 45 mg, 90 mg, 135 mg, 180 mg, or PBO weekly x 5 wks, then EOW. @wk 24 DAS28-CRP <2·6 5%, 16%. 19%, 14%, 14% respectively and 3% in PBO. Otilimab failed to meet primary endpoint. https://t.co/14QqyeTcuP (Twitter) - Oct 8, 2020
- ||| otilimab (GSK3196165) / GSK
He's been given a dose of otilimab - a drug currently under investigation as a potential treatment for #RheumatoidArthritis. https://t.co/xdXC4AmURI via @SkyNews #COVID_19 #Coronavirus (Twitter) - Sep 29, 2020
- || Clinical, Journal: Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. (Pubmed Central) - Jul 8, 2020
Recruiting --> Active, not recruiting This SLR informed the task force regarding the evidence base of various therapeutic regimen for the development of the update of EULAR's RA management recommendation.
- |||||| otilimab (GSK3196165) / GSK
Enrollment open, Combination therapy: contRAst 3: Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors (clinicaltrials.gov) - Jun 25, 2020
P3, N=525, Recruiting, Sponsor: GlaxoSmithKline
This SLR informed the task force regarding the evidence base of various therapeutic regimen for the development of the update of EULAR's RA management recommendation. Suspended --> Recruiting
- |||||| otilimab (GSK3196165) / GSK
Enrollment open, Combination therapy: contRAst 1: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (clinicaltrials.gov) - Jun 25, 2020
P3, N=1500, Recruiting, Sponsor: GlaxoSmithKline
Suspended --> Recruiting Suspended --> Recruiting
- |||||| otilimab (GSK3196165) / GSK
Enrollment open, Combination therapy: contRAst 2: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) (clinicaltrials.gov) - Jun 22, 2020
P3, N=1500, Recruiting, Sponsor: GlaxoSmithKline
Suspended --> Recruiting Suspended --> Recruiting
- ||| otilimab (GSK3196165) / GSK
Indeed. Just heard about this recently about TNF trials. Has anyone heard any insight on UST given encouraging reports from @SecureIBD ? I know some others developing rheum agents such as otilimab may show promise for #covid19 (no data in IBD to my knowledge) (Twitter) - Jun 16, 2020
- |||| otilimab (GSK3196165) / GSK
Enrollment open: OSCAR: Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease (clinicaltrials.gov) - Jun 4, 2020
P2, N=800, Recruiting, Sponsor: GlaxoSmithKline
Suspended --> Recruiting Not yet recruiting --> Recruiting
- |||||| otilimab (GSK3196165) / GSK
Enrollment open: contRAst X: Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA) (clinicaltrials.gov) - May 19, 2020
P3, N=2640, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| otilimab (GSK3196165) / GSK
New P2 trial: OSCAR: Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease (clinicaltrials.gov) - May 6, 2020
P2, N=800, Not yet recruiting, Sponsor: GlaxoSmithKline
- ||||||||| otilimab (GSK3196165) / GSK
Trial suspension, Combination therapy: contRAst 1: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (clinicaltrials.gov) - Apr 27, 2020
P3, N=1500, Suspended, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Recruiting --> Suspended
- ||||||||| otilimab (GSK3196165) / GSK
Trial suspension, Combination therapy: contRAst 2: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) (clinicaltrials.gov) - Apr 27, 2020
P3, N=1500, Suspended, Sponsor: GlaxoSmithKline
Recruiting --> Suspended Recruiting --> Suspended
- ||||||||| otilimab (GSK3196165) / GSK
Trial suspension, Combination therapy: contRAst 3: Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors (clinicaltrials.gov) - Apr 27, 2020
P3, N=525, Suspended, Sponsor: GlaxoSmithKline
Recruiting --> Suspended Recruiting --> Suspended
- | Xeljanz (tofacitinib) / Pfizer, Marche Polytechnic University
Review, Journal: Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects. (Pubmed Central) - Apr 23, 2020
Mainly because of this reason, nowadays the development program of most GM-CSF blockers for RA has been discontinued, with the exception of otilimab, which is under evaluation in two phase III RCTs with a head-to head non-inferiority design against tofacitinib...Phase II trials are ongoing with the aim of evaluating mavrilimumab for the treatment of giant cell arteritis, and namilumab for the treatment of spondyloarthritis...This review aims to describe in detail the available evidence on the GM-CSF blocking pathway in RA management, paving the way to a possible alternative treatment for RA patients. Novel insights regarding the potential use of GM-CSF blockers for alternative indications will be also addressed.
- |||| otilimab (GSK3196165) / GSK
Trial primary completion date, Combination therapy: contRAst 3: Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors (clinicaltrials.gov) - Apr 12, 2020
P3, N=525, Recruiting, Sponsor: GlaxoSmithKline
Novel insights regarding the potential use of GM-CSF blockers for alternative indications will be also addressed. Trial primary completion date: Jan 2022 --> May 2022
- |||| otilimab (GSK3196165) / GSK
Trial primary completion date, Combination therapy: contRAst 1: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (clinicaltrials.gov) - Apr 12, 2020
P3, N=1500, Recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Jan 2022 --> May 2022 Trial primary completion date: Jul 2021 --> May 2022
- |||| otilimab (GSK3196165) / GSK
Trial primary completion date, Combination therapy: contRAst 2: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) (clinicaltrials.gov) - Apr 12, 2020
P3, N=1500, Recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Jul 2021 --> May 2022 Trial primary completion date: Jul 2021 --> May 2022
- |||||||||| otilimab (GSK3196165) / GSK
New P3 trial: contRAst X: Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Apr 2, 2020
P3, N=2640, Not yet recruiting, Sponsor: GlaxoSmithKline